MedRx Co., Ltd

4586.T
Drug Manufacturers - Specialty & Generic
2026/11/17 21:02 Updated
Market Cap: $20.8M (¥3.3B)
Stock Price: $0.31 (¥50)
Exchange Rate: 1 USD = ¥159.49

Notice of Completion of Exercise of the 35th Share Acquisition Rights Issued by Third-Party Allotment (with Exercise Price Adjustment Clause) and Monthly Exercise Status

All exercises of the 35th share acquisition rights have been completed. In the subject month, 28,396 rights were exercised (19.21% of the total issued 147,820), and deliveries during the month totaled 2,839,600 shares including multiple exercise dates since the start of the month. The remaining unexercised rights are now zero. The total number of issued shares is 74,147,100 shares and the capital is 418 million yen.

Importance:
Page Updated: November 17, 2026
IR Disclosure Date: November 17, 2026

Key Figures

  • Total number of issued shares: 74,147,100 shares
  • Capital: 418 million yen
  • Number of these share acquisition rights issued: 147,820 cases

AI要約

Completion of Exercise of Share Acquisition Rights and Monthly Exercise Status

Today, payment for all exercises of the 35th share acquisition rights issued by third-party allotment was completed. During the subject month, 2,839,600 shares were delivered, and the number of share acquisition rights exercised in the month was 28,396 cases (19.21% of the total issued). All unexercised rights have been fully exercised, resulting in zero remaining rights. The current total number of issued shares is 74,147,100 shares and capital is 418 million yen.

Proceeds and Future Share Structure

The funds procured from the exercise of the share acquisition rights amount to 718 million yen (approximate net proceeds), and the allottee is Growth Capital Co., Ltd. The issuance date was June 5, 2026, and with the completion of these exercises, the exercise restriction ratio stands at 4.78% (combined for three or more points). The shareholder composition and dilution impact are finalized with the completion of these exercises, and there are no additional share acquisition rights remaining.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

MedRx Co., Ltd

Company overview · Stock price · Financial data · All IR

View company page →